Targeted fusion by neural stem cells as new biologics for cancer therapy

Chun-Ting Wu, Raphael Ferreira, George Church

Despite recent successful outcomes of CAR-T in hematological tumors, its effects on solid tumors, including glioma, only showed limited efficacy. The challenge of treating solid tumors is the immunosuppressive tumor microenvironment that inhibits the functions of immune system. Here, we designed a novel biologic- engineered neural stem cells (NSCs), which can home to glioma, fuse to cancer cells upon recognizing tumor antigens by specially engineered fusion proteins, and trigger fusion-specific protein expression. By doing so, we can initiate targeted cytokine expression to excite immune responses at the tumors’ sites. This novel biologic provides brand new approaches for engineered cells to eliminate cancer.

BTIP Agenda

In-person convening and light dinner: 5:30 – 5:45pm Eastern Time (US and Canada)

Zoom presentation: 5:45 – 6:45pm Eastern Time (US and Canada)

In-person networking: 6:45 – 7:00pm Eastern Time (US and Canada)

Contact

For more information about BTIP or to request an invitation, please contact Ifat Rubin-Bejerano, Senior Director of Translational Research.